Tocilizumab (International)
In the US, Tocilizumab (tocilizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat COVID-19, Cytokine Release Syndrome, Giant Cell Arteritis, Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Still's Disease, Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L04AC07
CAS registry number (Chemical Abstracts Service)
0375823-41-9
Chemical Formula
C6428-H9976-N1720-O2018-S42
Molecular Weight
144985
Therapeutic Categories
Immunosuppressant
Monoclonal antibody
Chemical Name
immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide wit human-mouse monoclonal MRA kappa-chain, dimer (WHO)
Foreign Names
- Tocilizumabum (Latin)
- Tocilizumab (German)
- Tocilizumab (French)
- Tocilizumab (Spanish)
Generic Names
- Tocilizumab (OS: USAN)
- Tocilizumab (Genetical Recombination) (OS: JAN)
- Atlizumab (IS)
- MRA (IS)
- R-1569 (IS)
Brand Names
- Actembra
Roche, Egypt - Actemra
Chugai, Georgia; Chugai Pharma, Oman; Chugai Pharmaceutical, Japan; F. Hoffmann-La Roche, Macedonia; Galenika AD, Serbia; Genentech, United States; Hoffmann-La Roche, Canada; Productos Roche, Chile; Roche, Armenia; Roche, Netherlands Antilles; Roche, Argentina; Roche, Aruba; Roche, Azerbaijan; Roche, Bosnia & Herzegowina; Roche, Belarus; Roche, Ecuador; Roche, Hong Kong; Roche, India; Roche, Kyrgyzstan; Roche, Moldova; Roche, Myanmar; Roche, Malaysia; Roche, New Zealand; Roche, Oman; Roche, Peru; Roche, Philippines; Roche, Paraguay; Roche, Russian Federation; Roche, Thailand; Roche, Turkmenistan; Roche, Tunisia; Roche, Uruguay; Roche, Vietnam; Roche, South Africa; Roche D.O.O., Serbia; Roche Products, Australia; Vetter, Georgia; Vetter, Russian Federation; Roche Pharma Schweiz, Switzerland - ACTEMRA
Roche Pharmaceutical, China - Actemra 162mg
Roche, Israel - Actemra 200mg/10ml
Roche, Turkey - Actemra 20mg/ml
Roche, Israel - Actemra 400mg/20ml
Roche, Turkey - Actemra 80mg/4ml
Roche, Turkey - Acterma
Chugai Pharma, Kenya; Roche, Brazil - Acterma SC
Roche, Brazil - Aktempa
Roche, Ukraine - Roaccutane
Roche, Cyprus - RoActemra
Hoffmann-La Roche Ltd, Latvia; Roche, Belgium; Roche, Czech Republic; Roche, Denmark; Roche, Estonia; Roche, Spain; Roche, Finland; Roche, France; Roche, Greece; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Lithuania; Roche, Mexico; Roche, Norway; Roche, Poland; Roche, Sweden; Roche - Germania, Romania; Roche Products, United Kingdom; Roche Registration, Netherlands; Roche Registration Limited, Iceland; Roche Registration, Slovenia - RoActemra 162 mg
Roche, Hungary - RoActemra 162mg
Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria - RoActemra 20 mg/ml
Roche, Hungary - RoActemra 20mg/ml
Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria
Glossary
Term | Definition |
---|---|
IS | Inofficial Synonym |
JAN | Japanese Accepted Name |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.